However, a study found that genetic deficiency of MMP9 enhanced CAC development and reduced survival in AOM/DSS-treated mice (165) suggesting an anti-tumoral role in CAC in contrast to APC-mutation-driven CRC, where genetic deficiency of MMP9 decreased tumour number by 40% in Apcmin/+ mice (166). This evidence concerns the gene MMP9 and neoplasm.